Hallmarks of aging in systemic sclerosis: implications for pathogenesis, multimorbidity, and therapeutic development.
- 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- 2Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Abstract
Systemic sclerosis (SSc) is a heterogeneous autoimmune disease characterised by marked clinical variability and a substantial burden of comorbidities, which may reflect underlying biological aging processes. Although chronological age influences disease presentation and prognosis, growing evidence suggests that biological aging processes may contribute directly to disease pathogenesis. Hallmarks of aging, including chronic low-grade inflammation and immunosenescence, have been identified across tissues affected by SSc and may drive persistent immune activation, vascular injury, defective tissue repair, and progressive fibrosis. Aging is increasingly recognised as a tissue-specific and multidimensional process rather than a uniform consequence of chronological time. Differential aging trajectories across organs may influence susceptibility to SSc-related damage, shaping heterogeneous clinical phenotypes. Aging-related mechanisms may also affect disease presentation, severity, comorbidities, and outcomes across the life course and contribute to therapeutic challenges in routine care. In this review, we examine current evidences linking molecular and cellular mechanism of aging to the pathogenesis, clinical manifestations, and outcomes of SSc. We discuss the implications for comorbidity burden and treatment decision-making. A deeper understanding of aging-related mechanisms may provide a unifying framework for disease heterogeneity and support the development of more individualised management strategies and therapeutic approaches in SSc.
Related
- Dihydromyricetin and Neuroinflammation: Implications for CNS Disorders and Therapeutic Development
- Tumor heterogeneity: development, mechanisms, and therapeutic implications
- 8-aminoguanine as a therapeutic strategy to reverse hallmarks of urothelial cell aging
- Treatment burden and cardiometabolic multimorbidity: Implications for the Philippines
- From Molecular Pathogenesis to Therapeutic Innovations in Human Cytomegalovirus Research
BibTeX
@article{iacovantuono2026hallmarks,
title = {{Hallmarks of aging in systemic sclerosis: implications for pathogenesis, multimorbidity, and therapeutic development.}},
author = {Maria Iacovantuono and Amela Hukara and Gesa Marie Sauer and Oliver Distler and Maria Sole Chimenti and Gabriela Kania and Cosimo Bruni and Muriel Elhai},
journal = {EULAR rheumatology open},
year = {2026},
month = oct,
doi = {10.1016/j.ero.2026.100256},
url = {https://europepmc.org/article/MED/42926811},
note = {CC BY},
}
RIS
TY - JOUR
TI - Hallmarks of aging in systemic sclerosis: implications for pathogenesis, multimorbidity, and therapeutic development.
AU - Maria Iacovantuono
AU - Amela Hukara
AU - Gesa Marie Sauer
AU - Oliver Distler
AU - Maria Sole Chimenti
AU - Gabriela Kania
AU - Cosimo Bruni
AU - Muriel Elhai
PY - 2026
DA - 2026/10/14
JO - EULAR rheumatology open
DO - 10.1016/j.ero.2026.100256
UR - https://europepmc.org/article/MED/42926811
AB - Systemic sclerosis (SSc) is a heterogeneous autoimmune disease characterised by marked clinical variability and a substantial burden of comorbidities, which may reflect underlying biological aging processes. Although chronological age influences disease presentation and prognosis, growing evidence suggests that biological aging processes may contribute directly to disease pathogenesis. Hallmarks of aging, including chronic low-grade inflammation and immunosenescence, have been identified across tissues affected by SSc and may drive persistent immune activation, vascular injury, defective tissue repair, and progressive fibrosis. Aging is increasingly recognised as a tissue-specific and multidimensional process rather than a uniform consequence of chronological time. Differential aging trajectories across organs may influence susceptibility to SSc-related damage, shaping heterogeneous clinical phenotypes. Aging-related mechanisms may also affect disease presentation, severity, comorbidities, and outcomes across the life course and contribute to therapeutic challenges in routine care. In this review, we examine current evidences linking molecular and cellular mechanism of aging to the pathogenesis, clinical manifestations, and outcomes of SSc. We discuss the implications for comorbidity burden and treatment decision-making. A deeper understanding of aging-related mechanisms may provide a unifying framework for disease heterogeneity and support the development of more individualised management strategies and therapeutic approaches in SSc.
SN - 3050-7081
ER -